Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis

Brett Stevens,Amanda Winters,Jonathan A. Gutman,Aaron Fullerton, Gregory Hemenway,Derek Schatz,Nicholas Miltgen,Qi Wei,Taher Abbasi,Shireen Vali,Neeraj K. Singh,Leylah Drusbosky,Christopher R. Cogle,Andrew Hammes,Diana Abbott,Craig T. Jordan,Clayton Smith,Daniel A. Pollyea

Leukemia Research（2019）

引用 4|浏览54

暂无评分

摘要

•Azacitidine + lenalidomide is active in some relapsed/refractory AML patients.•Tolerability of this regimen was in some cases poor.•A computational biological modeling approach predicted responders to this regimen.•Toxic, low response rate therapies have a role if response prediction is robust.

查看译文

关键词

Acute myeloid leukemia,Relapsed,Lenalidomide,Azacitidine,Computational modeling,Prediction

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要